A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single-Agent Belantamab Mafodotin (Belamaf) Compared With Pomalidomide Plus Low-Dose Dexamethasone (Pd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) (DREAMM-3)

被引：0
|
作者：
Weisel, Katja [1 ]
Hungria, Vania T. M. [2 ]
Radinoff, Atanas [3 ]
Delimpasi, Sosana [4 ]
Gabor, Mikala [5 ]
Masszi, Tamas [6 ]
Li, Jian [7 ]
Capra, Marcelo [8 ]
Matsumoto, Morio [9 ]
Sule, Neal [10 ]
Li, Mary [10 ]
McKeown, Astrid [11 ]
He, Wei [12 ]
Bright, Shelley [10 ]
Currie, Brooke [13 ]
Boyle, Julia [14 ]
Opalinska, Joanna [10 ]
Dimopoulos, Meletios Athanasios [15 ]
机构：
[1] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany
[2] Dept Hematol, Clin Sao Germano, Sao Paulo, Brazil
[3] Univ Hosp St Ivan Rilski EAD, Sofia, Bulgaria
[4] Gen Hosp Evangelismos, Athens, Greece
[5] Natl Inst Haematol & Infect Dis, South Pest Cent Hosp, Budapest, Hungary
[6] Semmelweis Univ, Dept Internal Med & Haematol, Budapest, Hungary
[7] Chinese Acad Med Sci & Peking Union Med Coll, Dept Hematol, Peking Union Med Coll Hosp, Beijing, Peoples R China
[8] Hosp Mae Deus, Ctr Integrado Hematol & Oncol, Porto Alegre, RS, Brazil
[9] Natl Hosp Org, Shibukawa Med Ctr, Shibukawa, Japan
[10] GSK, Upper Providence, PA USA
[11] GSK, Stevenage, Herts, England
[12] GSK, Waltham, MA USA
[13] GSK, Rockville, MD USA
[14] GSK, London, England
[15] Natl & Kapodistrian Univ Athens, Sch Med, Athens, Greece
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
multiple myeloma; belantamab mafodotin; relapsed/refractory multiple myeloma; phase III;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MM-509
引用
收藏
页码：S504 / S505
页数：2
相关论文
共 50 条
  • [1] A phase 3, open-label, randomized study to evaluate the efficacy and safety of single-agent belantamab mafodotin (belamaf) compared to pomalidomide plus low-dose dexamethasone (Pd) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): DREAMM-3.
    Weisel, Katja
    Hungria, Vania T. M.
    Radinoff, Atanas
    Delimpasi, Sosana
    Mikala, Gabor
    Masszi, Tamas
    Li, Jian
    Capra, Marcelo
    Matsumoto, Morio
    Sule, Neal
    Li, Mary
    McKeown, Astrid
    He, Wei
    Bright, Shelley
    Currie, Brooke
    Boyle, Julia
    Opalinska, Joanna
    Dimopoulos, Meletios A.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [2] DREAMM-3: a phase III, open-label, randomized study evaluating the efficacy and safety of single agent belantamab mafodotin vs pomalidomide plus dexamethasone in Relapsed/ Refractory Multiple Myeloma (RRMM)
    Weisel, K.
    Dimopoulos, M. A.
    Hungria, V. T. M.
    Radino, A.
    Delimpasi, S.
    Mikala, G.
    Masszi, T.
    Li, J.
    Capra, M.
    Matsumoto, M.
    Sule, N.
    Li, M.
    McKeown, A.
    He, W.
    Bright, S.
    Currie, B.
    Boyle, J.
    Opalinska, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 233 - 234
  • [3] Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study
    Dimopoulos, Meletios Athanasios
    Hungria, Vania T. M.
    Radinoff, Atanas
    Delimpasi, Sosana
    Mikala, Gabor
    Masszi, Tamas
    Li, Jian
    Capra, Marcelo
    Maiolino, Angelo
    Pappa, Vasiliki
    Chraniuk, Dominik
    Osipov, Iurii
    Leleu, Xavier
    Low, Michael
    Matsumoto, Morio
    Sule, Neal
    Li, Mary
    McKeown, Astrid
    He, Wei
    Bright, Shelley
    Currie, Brooke
    Perera, Sue
    Boyle, Julia
    Roy-Ghanta, Sumita
    Opalinska, Joanna
    Weisel, Katja
    LANCET HAEMATOLOGY, 2023, 10 (10): : E801 - E812
  • [4] Dreamm-3: A Phase 3, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin (GSK2857916) Monotherapy Compared with Pomalidomide Plus Low-Dose Dexamethasone (Pom/Dex) in Participants with Relapsed/Refractory Multiple Myeloma (RRMM)
    Weisel, Katja
    Hopkins, Thomas G.
    Fecteau, Doug
    Bao, Weichao
    Quigley, Corinne
    Jewell, Roxanne C.
    Nichols, Maureen
    Opalinska, Joanna
    BLOOD, 2019, 134
  • [5] Patient-Reported Outcomes in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) Treated With Belantamab Mafodotin (Belamaf) Versus Pomalidomide Plus Low-Dose Dexamethasone (Pd) in the DREAMM-3 Study
    Hungria, Vania
    Weisel, Katja
    Currie, Brooke
    Perera, Sue
    Sule, Neal
    He, Wei
    Davy, Katherine
    McKeown, Astrid
    Sapra, Sandhya
    Nelsen, Linda
    Li, Mary
    Barale, Sophie
    Boyle, Julia
    McPoyle, Kaytlyn
    Dimopoulos, Meletios Athanasios
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S505 - S505
  • [6] Patient (pt)-reported outcomes in pts with relapsed/refractory multiple myeloma (RRMM) treated with belantamab mafodotin (belamaf) vs pomalidomide/low dose dexamethasone (Pd) in the phase III, open-label, randomized, multicenter DREAMM-3 study
    Weisel, K.
    Hungria, V.
    Currie, B.
    Perera, S.
    Sule, N.
    He, W.
    McKeown, A.
    Sapra, S.
    Li, M.
    Barale, S.
    Boyle, J.
    McPoyle, K.
    Dimopoulos, M. A.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 180 - 180
  • [7] Updated Results From DREAMM-3, a Phase 3 Study of Belantamab Mafodotin (Belamaf) Versus Pomalidomide Plus Dexamethasone in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM)
    Hungria, Vania T. M.
    Weisel, Katja
    Radinoff, Atanas
    Delimpasi, Sosana
    Mikala, Gabor
    Masszi, Tamas
    Li, Jian
    Capra, Marcelo
    Maiolino, Angelo
    Pappa, Vasiliki
    Chraniuk, Dominik
    Osipov, Iurii
    Leleu, Xavier
    Low, Michael
    Kouri, Fotini
    Liboon, John
    Brawley, Chris
    Lewis, Eric
    Tubel, Gabriela
    Li, Mary
    McKeown, Astrid
    Roy-Ghanta, Sumita
    Opalinska, Joanna
    Dimopoulos, Meletios
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S261 - S262
  • [8] DREAMM-8: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin with Pomalidomide and Dexamethasone (B- Pd) Vs Pomalidomide Plus Bortezomib and Dexamethasone (PVd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
    Trudel, Suzanne
    Davis, Randy
    Lewis, Nicole M.
    Bakshi, Kalpana K.
    Chopra, Bikramjit
    de Oca, Rocio Montes
    Ferron-Brady, Geraldine
    Eliason, Laurie
    Kremer, Brandon E.
    Gupta, Ira
    Wu, Frank S.
    BLOOD, 2020, 136
  • [9] DREAMM-8: A phase III study of the efficacy and safety of belantamab mafodotin with pomalidomide and dexamethasone vs pomalidomide plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma
    Trudel, Suzanne
    Davis, Randy
    Lewis, Nicole M.
    Bakshi, Kalpana K.
    Chopra, Bikramjit
    de Oca, Rocio Montes
    Ferron-Brady, Geraldine
    Eliason, Laurie
    Kremer, Brandon E.
    Stowell, Delia
    Gupta, Ira
    Wu, Frank S.
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 177 - 177
  • [10] DREAMM-7: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin (Belamaf) with Bortezomib, and Dexamethasone (B-Vd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
    Rifkin, Robert M.
    Boyd, Kevin
    Grosicki, Sebastian
    Kim, Kihyun
    Di Raimondo, Francesco
    Dimopoulos, Meletios A.
    Weisel, Katja
    Arnulf, Bertrand
    Hajek, Roman
    Hungria, Vania T. M.
    Spencer, Andrew
    Davis, Randy
    Riccio, Antonio
    Kim, Chanbin
    Wilkes, Jodie
    Rutledge, Ruth
    Talekar, Mala
    Kremer, Brandon E.
    Gupta, Ira
    Mateos, Maria-Victoria
    BLOOD, 2020, 136
12345